← Back to Search

Clinical Validation Group for Bladder Cancer

N/A
Recruiting
Research Sponsored by PPsanalytics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sensitivity and Specificity of UriFind assay in detecting early stage Bladder Cancer

Trial Design

1Treatment groups
Experimental Treatment
Group I: Clinical Validation GroupExperimental Treatment1 Intervention
Patients with suspected bladder cancer (including hematuria, inflammatory bladder, suspicious ultrasound results)

Find a Location

Who is running the clinical trial?

AnchorDx Medical Co., Ltd.Industry Sponsor
5 Previous Clinical Trials
16,710 Total Patients Enrolled
PPsanalyticsLead Sponsor
1 Previous Clinical Trials
500 Total Patients Enrolled
Specialty NetworksUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby May 2024